COMMUNIQUÉS West-GlobeNewswire

VisioCore Under Investigation: The Advanced Eyesight Vision Support Capsules with Organic Ingredients
13/05/2026
VisioCore Scam or Legit? Lutein, Zeaxanthin, and Bilberry Formula Ingredients, $59 Pricing, and 60-Day Guarantee Explained for 2026 Aurora, CO, May 12, 2026 (GLOBE NEWSWIRE) -- These statements have not been evaluated [...]
GMR Solutions Inc. Announces Pricing of its Initial Public Offering
13/05/2026
LEWISVILLE, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- GMR Solutions Inc. (“GMR”) today announced the pricing of an initial public offering of 31,914,893 shares of its Class A common stock at $15.00 per share. Shares of [...]
Nyxoah Reports First Quarter 2026 Financial and Operating Results
12/05/2026
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio [...]
Stereotaxis Reports 2026 First Quarter Financial Results & Business Updates
12/05/2026
Proprietary robotically-navigated MAGiC catheter received U.S. FDA approval in January and is now being utilized at multiple sites across the United States as well as Europe Synchrony digital operating room system [...]
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
12/05/2026
Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE [...]
Lumexa Imaging Announces First Quarter 2026 Results
12/05/2026
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, [...]
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
12/05/2026
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug [...]
Spectral AI Announces 2026 First Quarter Financial Results
12/05/2026
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. ( [...]
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced [...]
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
12/05/2026
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to [...]
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial [...]
Crescent Biopharma Announces Grants of Inducement Awards
12/05/2026
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
12/05/2026
Châtillon, France, May 12, 2026 DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT [...]
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
12/05/2026
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
12/05/2026
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and [...]
COSCIENS Biopharma Inc. Reports Q1 2026 Results
12/05/2026
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the first quarter ended [...]
Sanuwave Announces Revenues and Financial Results for Q1 FY2026
12/05/2026
Q1 2026 revenues were $9.6 million , up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3% , versus 79.0% in Q1 2025. GAAP Operating [...]
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
12/05/2026
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well- [...]
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
12/05/2026
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]

Pages